PATANASE (olopatadine hydrochloride) Nasal Spray, 665 micrograms (mcg) is a metered-spray solution for intranasal administration. Olopatadine hydrochloride, the active component of PATANASE Nasal Spray, is a white, water-soluble crystalline powder.
PATANASE Nasal Spray is indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
Media Articles Related to Patanase (Olopatadine Nasal)
Allergic Rhinitis: 3 Years of Immunotherapy Needed
Source: Medscape Allergy & Clinical Immunology Headlines [2017.02.14]
When treatment was shortened from 3 years to 2, sublingual immunotherapy proved no better than placebo for patients with grass pollen allergy.
Medscape Medical News
Hay Fever (Allergic Rhinitis)
Source: MedicineNet Allergic Cascade Specialty [2016.10.07]
Title: Hay Fever (Allergic Rhinitis)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/7/2016 12:00:00 AM
Published Studies Related to Patanase (Olopatadine Nasal)
Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis. [2011.05]
Allergic rhinitis (AR) is highly prevalent in children...
Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. [2011.03]
Olopatadine hydrochloride nasal spray 0.6% (OLO) and azelastine nasal spray 137 micrograms (AZE) are effective in treating allergic rhinitis and AZE is indicated for nonallergic vasomotor rhinitis (VMR). This study evaluates the relative safety and efficacy of OLO and AZE in patients with VMR.
Mometasone furoate nasal spray for moderate-to-severe nasal congestion in
subjects with seasonal allergic rhinitis. 
Nasal congestion is a frequent, bothersome symptom of seasonal allergic rhinitis
(SAR). Mometasone furoate nasal spray (MFNS) has established efficacy in treating
nasal allergy symptoms, but no study has been conducted with the primary purpose
of evaluating MFNS for relief of congestion...
Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. [2010.07]
OBJECTIVE: The efficacy of antihistamines in perennial allergic rhinitis in children has been evaluated in studies using active comparators, whereas placebo-controlled studies are very few. A randomized, multicenter, double-blind, parallel-group clinical study was carried out to evaluate the dose-response relationship and superiority of olopatadine hydrochloride over placebo in children aged 7 to 16 years with perennial allergic rhinitis... CONCLUSIONS: Olopatadine hydrochloride 5 mg twice daily is an effective and safe treatment for perennial allergic rhinitis in children.
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. [2010.03]
The combination of intranasal antihistamines and intranasal corticosteroids results in superior relief of seasonal allergic rhinitis (SAR) symptoms compared with monotherapy. This study was designed to evaluate the safety and efficacy of olopatadine hydrochloride nasal spray, 0.6% (OLO), administered in combination with fluticasone nasal spray, 50 micrograms (FNS), relative to azelastine nasal spray, 0.1% (AZE), administered in combination with FNS in the treatment of SAR.
Clinical Trials Related to Patanase (Olopatadine Nasal)
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis [Completed]
The purpose of this study was to assess local nasal adverse effects, as well as systemic
effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3. 7 and Patanase
Vehicle, pH 7. 0 in patients with perennial allergic rhinitis (PAR).
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects [Recruiting]
The purpose of this study is to evaluate Olopatadine 0. 2% QD (once per day) compared to
Olopatadine 0. 1% BID (twice per day) in the treatment of ocular itching associated with
Safety and Comfort of AL-4943A Ophthalmic Solution [Completed]
Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects [Completed]
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model [Completed]
The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic
solution for the treatment of ocular itching associated with allergic conjunctivitis using
the Conjunctival Allergen Challenge (CAC) model.